Sign up Australia
Proactive Investors - Run By Investors For Investors

Phylogica patents peptide technology to develop cell-penetrating drugs

Phylogica patents peptide technology to develop cell-penetrating drugs

Phylogica (ASX:PYC) has patented an improvement to its Phylomer peptide platform that will allow more efficient screening of its library of billions of naturally occurring peptides and identify those with the highest potential to target disease proteins inside the cells.

To develop a new generation of therapies, the peptides need to be able to deliver biologics drugs to cells where most targets are. To do this effectively, they need to penetrate natural cell membranes; target particular parts of the cell such as nuclei and ensure that drug cargos are not trapped in endosomes.

There is a significant requirement for technologies that improve the efficiency of the delivery of large therapeutic molecules such as proteins into cells as cell membranes can be major impediments.

Phylogica’s Endosomal Escape Trap enables the efficient identification of Phylomer cell-penetrating peptide-drug conjugates that not only deliver the therapeutic payload across the cell membrane, but also efficiently escape from the endosome so that the drug can have a therapeutic effect.

It is partnering with Genentech, a member of Roche Group (VTR:ROG); MedImmune- the biologics arm of AstraZeneca (LON:AZN); Pfizer and Janssen Biotech.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.



Register here to be notified of future PYC Company articles
View full PYC profile

PHYLOGICA LIMITED Timeline

Newswire
October 06 2015
Newswire
November 25 2014
Newswire
November 07 2013

Related Articles

shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study
genomics.jpg
October 05 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.
Blood testing
February 14 2017
Identifying cancer cells early is a key part of combatting the disease, and ANGLE's Parsortix device looks to be developing into a key ally.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use